For Canadian residents only

Safety Information & References Product Monograph

Coverage

LIBTAYO is now publicly reimbursed in most provinces.*
Restrictions apply. Coverage restrictions in addition to the indicated condition may apply.

Please note that LIBTAYO is:

  • Covered in Ontario through the New Drug Funding Program
  • Covered in Alberta as a Group 2 Drug List

* LIBTAYO is now covered in Alberta, Ontario, Quebec, Saskatchewan, New Brunswick, and Manitoba.

SAFETY PROFILE

Learn about the safety and tolerability profile of LIBTAYO in patients with advanced CSCC.

Learn more

EFFICACY PROFILE

Explore the efficacy profile of LIBTAYO, including cases seen from the trials.

Learn more

STUDY DESIGN

Learn the details behind Study 1423 and Study 1540, two clinical trials used to evaluate the efficacy and safety profile of LIBTAYO.

Learn more